Standard versus double dose dolutegravir in patients with HIV-associated tuberculosis: a phase 2 non-comparative randomised controlled (RADIANT-TB) trial.

Griesel, Rulan; Hill, Andrew; Meintjes, Graeme; Maartens, Gary

Griesel, Rulan; Hill, Andrew; Meintjes, Graeme; Maartens, Gary.

Afiliação

Griesel R; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Hill A; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Meintjes G; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Maartens G; Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Wellcome Open Res ; 6: 1, 2021.

Article em En | MEDLINE | ID: mdl-33954265

Palavras-chave

Dolutegravir; drug-drug interaction; rifampicin; tuberculosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Guideline / Risk_factors_studies Idioma: En Revista: Wellcome Open Res Ano de publicação: 2021 Tipo de documento: Article País de afiliação: África do Sul

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google